vision-biotech demonstrates its commitment to biosensor market with the launch of a new grade of FAD-GDH


vision-biotech (VBT) has announced the launch of a next generation FAD-dependent Glucose Dehydrogenase (FAD-GDH) for blood glucose monitoring.

For people with diabetes, it is critical that they are able to measure their blood glucose levels accurately.聽 This need for greater accuracy for end users, along with tightening regulatory requirements, is driving the development of next generation tests for biosensor manufacturers.

VBT鈥檚 new grade of FAD-GDH, product code GLD3, offers reduced xylose interference; it has a higher specificity to glucose and reduced cross-reactivity with other sugars, increasing test accuracy.聽 The higher reactivity of the enzyme provides a faster signal and its improved stability enhances reliable strip performance, critical to both end users and manufacturers.

GLD3 is the latest addition to VBT鈥檚 market leading range of enzymes for blood glucose monitoring.聽 Used in over 5 billion test strips every year, VBT has been manufacturing Glucose Oxidase for over forty years. The company introduced the first grade of the recombinant FAD-GDH in 2013.

VBT鈥檚 improved FAD-GDH with reduced xylose interference is available for testing now; customers can find out more or request an evaluation sample here.聽